Voyager Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Voyager Therapeutics ended Q2 2026 with $148.8M cash (sufficient runway into 2028). Two tau-targeted Alzheimer's programs advanced: VY7523 (anti-tau antibody) expects tau PET imaging efficacy data in Q4 2026; VY1706 (tau-silencing gene therapy) received FDA IND clearance and Health Canada CTA clearance, with dosing expected to begin Q4 2026. Net loss for Q2 2026 was $24.5M vs. $33.4M in Q2 2025; collaboration revenue declined to $3.2M from $5.2M year-over-year.
Why this rating
Cash runway into 2028 and two near-term clinical inflection points are meaningful for a $144M company; progress de-risks pipeline but near-term value dependent on Q4 2026 data outcomes.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.